Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

446
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
446
Infection01:20

Infection

8.9K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
8.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

74
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
74
Synthetic Biology02:55

Synthetic Biology

5.0K
Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
5.0K
The Proteasome02:18

The Proteasome

9.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026
Same author

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.

Cancer research·2026
Same author

Wide Ranging Neurobehavioral Phenotype in Individuals With Costello Syndrome.

American journal of medical genetics. Part A·2026
Same author

Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.

Molecular cancer therapeutics·2025
Same author

Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i>-mutated cancers.

Science signaling·2025
Same author

ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity.

Molecular cancer research : MCR·2024

Related Experiment Video

Updated: Oct 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

The RASopathies: from pathogenetics to therapeutics.

Katie E Hebron1, Edjay Ralph Hernandez1, Marielle E Yohe1

  • 1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Disease Models & Mechanisms
|February 18, 2022
PubMed
Summary

RASopathies are rare genetic disorders caused by RAS/MAPK pathway mutations. This review covers their pathogenesis, models, and potential targeted therapies, including those used for cancers.

Keywords:
Cardiofaciocutaneous syndromeCostello syndromeLegius syndromeNoonan syndromeRASRASopathies

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.3K
High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions
14:58

High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions

Published on: March 5, 2022

4.5K

Related Experiment Videos

Last Updated: Oct 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.3K
High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions
14:58

High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions

Published on: March 5, 2022

4.5K

Area of Science:

  • Genetics
  • Molecular Biology
  • Developmental Biology

Background:

  • RASopathies are a group of genetic disorders stemming from germline mutations in the RAS/MAPK signaling pathway.
  • These conditions, including neurofibromatosis type 1 and Noonan syndrome, exhibit overlapping clinical manifestations due to RAS/MAPK pathway dysfunction.
  • While individually rare, the collective incidence of RASopathies is significant.

Purpose of the Study:

  • To review the pathogenesis of genetic variants associated with RASopathies.
  • To explore the insights gained into RAS/MAPK signaling from studying these disorders.
  • To discuss emerging RASopathy genes and therapeutic strategies, including targeted agents.

Main Methods:

  • Review of existing literature on RASopathies, RAS/MAPK signaling, and therapeutic interventions.
  • Analysis of pathogenesis, genetic variants, and molecular mechanisms.
  • Examination of cell and animal models used in RASopathy research.
  • Evaluation of preclinical and clinical data for targeted therapies.

Main Results:

  • Germline mutations in RAS/MAPK pathway genes lead to a spectrum of RASopathies with shared clinical features.
  • Study of RASopathies has significantly advanced the understanding of RAS/MAPK signaling.
  • Various cell and animal models are available for studying RASopathy pathogenesis and testing therapeutics.
  • Emerging genes and targeted therapies, including those for RAS/MAPK-driven malignancies, show promise for RASopathy treatment.

Conclusions:

  • Understanding the pathogenesis of RASopathies provides crucial insights into RAS/MAPK pathway function.
  • Targeted therapies, particularly those developed for cancers, hold potential for treating patients with RASopathies.
  • Further research into emerging genes and therapeutic strategies is warranted to improve patient outcomes.